Logo image of GPCR

STRUCTURE THERAPEUTICS INC (GPCR) Stock Fundamental Analysis

NASDAQ:GPCR - Nasdaq - US86366E1064 - ADR - Currency: USD

23.765  +0.38 (+1.6%)

After market: 23.95 +0.18 (+0.78%)

Fundamental Rating

3

Overall GPCR gets a fundamental rating of 3 out of 10. We evaluated GPCR against 194 industry peers in the Pharmaceuticals industry. While GPCR has a great health rating, there are worries on its profitability. GPCR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

GPCR had negative earnings in the past year.
In the past year GPCR has reported a negative cash flow from operations.
GPCR Yearly Net Income VS EBIT VS OCF VS FCFGPCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

GPCR has a Return On Assets of -11.85%. This is in the better half of the industry: GPCR outperforms 69.19% of its industry peers.
GPCR has a better Return On Equity (-12.33%) than 75.14% of its industry peers.
Industry RankSector Rank
ROA -11.85%
ROE -12.33%
ROIC N/A
ROA(3y)-37.32%
ROA(5y)N/A
ROE(3y)-41.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GPCR Yearly ROA, ROE, ROICGPCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GPCR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GPCR Yearly Profit, Operating, Gross MarginsGPCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

GPCR has more shares outstanding than it did 1 year ago.
There is no outstanding debt for GPCR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GPCR Yearly Shares OutstandingGPCR Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 10M 20M 30M 40M
GPCR Yearly Total Debt VS Total AssetsGPCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

GPCR has an Altman-Z score of 22.27. This indicates that GPCR is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of GPCR (22.27) is better than 92.43% of its industry peers.
GPCR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 22.27
ROIC/WACCN/A
WACCN/A
GPCR Yearly LT Debt VS Equity VS FCFGPCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 27.63 indicates that GPCR has no problem at all paying its short term obligations.
GPCR's Current ratio of 27.63 is amongst the best of the industry. GPCR outperforms 96.76% of its industry peers.
A Quick Ratio of 27.63 indicates that GPCR has no problem at all paying its short term obligations.
The Quick ratio of GPCR (27.63) is better than 96.76% of its industry peers.
Industry RankSector Rank
Current Ratio 27.63
Quick Ratio 27.63
GPCR Yearly Current Assets VS Current LiabilitesGPCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 52.87% over the past year.
EPS 1Y (TTM)52.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, GPCR will show a small growth in Earnings Per Share. The EPS will grow by 5.63% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y61.71%
EPS Next 2Y27.17%
EPS Next 3Y10.95%
EPS Next 5Y5.63%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GPCR Yearly Revenue VS EstimatesGPCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
GPCR Yearly EPS VS EstimatesGPCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6 8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GPCR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GPCR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GPCR Price Earnings VS Forward Price EarningsGPCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GPCR Per share dataGPCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.17%
EPS Next 3Y10.95%

More info and screens

0

5. Dividend

5.1 Amount

GPCR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

STRUCTURE THERAPEUTICS INC

NASDAQ:GPCR (2/21/2025, 8:24:19 PM)

After market: 23.95 +0.18 (+0.78%)

23.765

+0.38 (+1.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)03-06 2025-03-06/amc
Inst Owners108.85%
Inst Owner Change-0.84%
Ins Owners2.46%
Ins Owner Change6.62%
Market Cap1.36B
Analysts85.56
Price Target86.19 (262.68%)
Short Float %43.57%
Short Ratio8.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.39%
Min EPS beat(2)-5.49%
Max EPS beat(2)22.26%
EPS beat(4)2
Avg EPS beat(4)-45.68%
Min EPS beat(4)-211.09%
Max EPS beat(4)22.26%
EPS beat(8)3
Avg EPS beat(8)-49.89%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.58%
PT rev (3m)-3.87%
EPS NQ rev (1m)-2.13%
EPS NQ rev (3m)13.97%
EPS NY rev (1m)0.55%
EPS NY rev (3m)-2.64%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.52
P/tB 1.52
EV/EBITDA N/A
EPS(TTM)-1.23
EYN/A
EPS(NY)-0.82
Fwd EYN/A
FCF(TTM)-1.82
FCFYN/A
OCF(TTM)-1.78
OCFYN/A
SpS0
BVpS15.66
TBVpS15.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.85%
ROE -12.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.32%
ROA(5y)N/A
ROE(3y)-41.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 307.21%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 27.63
Quick Ratio 27.63
Altman-Z 22.27
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)821.84%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.74%
EPS Next Y61.71%
EPS Next 2Y27.17%
EPS Next 3Y10.95%
EPS Next 5Y5.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-67.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-53.92%
EBIT Next 3Y-35.83%
EBIT Next 5Y-24.53%
FCF growth 1Y-131.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-127.18%
OCF growth 3YN/A
OCF growth 5YN/A